Teva shares climb as biosimilar approval and fresh bullish coverage support momentum

Teva Pharmaceutical Industries Ltd. (TEVA) is up 5.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of positive fundamental momentum and improving investor sentiment. This could be because investors are still reacting to Teva’s late-September FDA approval for DEGEVMA, while a recent new Buy rating with a $55 price target reinforced the view that Teva’s growth pipeline and biosimilar strategy can support further upside.

Details:

Teva announced FDA approval for DEGEVMA, a biosimilar to Xgeva, giving the company a second FDA-approved biosimilar in 2026 and expanding its denosumab portfolio.

The company said DEGEVMA is approved across all indications of the reference product, adding another commercial catalyst to its Pivot to Growth strategy.

A recent analyst initiation assigned TEVA a Buy rating and a $55 price target, highlighting confidence in the company’s combination of generics, biosimilars, and branded growth assets.

Teva also recently completed its transition from ADSs to ordinary shares trading directly on the NYSE, a step the company framed as broadening investor access to the stock.

Sources:

Teva Pharmaceuticals, SEC, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TEVA Insider Trading Activity

$TEVA insiders have traded $TEVA stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:

ROBERTO MIGNONE sold 367,600 shares for an estimated $14,356,801
ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) sold 106,563 shares for an estimated $3,633,308
EVAN LIPPMAN (EVP, Business Development) has made 0 purchases and 3 sales selling 60,258 shares for an estimated $2,162,657.
ERIC A HUGHES (See "Remarks") sold 25,578 shares for an estimated $892,050
MATTHEW SHIELDS (EVP, Global Operations) has made 0 purchases and 2 sales selling 26,184 shares for an estimated $853,876.
PLACID JOVER (See "Remarks") sold 12,827 shares for an estimated $447,350
AMIR WEISS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 9,445 shares for an estimated $355,301.
BRIAN SAVAGE (Interim Chief Legal Officer) has made 0 purchases and 3 sales selling 7,342 shares for an estimated $285,215.
RICHARD D FRANCIS (President and CEO) sold 6,153 shares for an estimated $211,355
RONIT SATCHI-FAINARO sold 415 shares for an estimated $15,458
TAL ZVI ZAKS sold 17 shares for an estimated $592

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$TEVA Hedge Fund Activity

We have seen 329 institutional investors add shares of $TEVA stock to their portfolio, and 254 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MEITAV INVESTMENT HOUSE LTD added 9,947,045 shares (+inf%) to their portfolio in Q2 2026, for an estimated $337,005,884
LINGOTTO INVESTMENT MANAGEMENT LLP removed 7,564,914 shares (-27.2%) from their portfolio in Q2 2026, for an estimated $256,299,286
JPMORGAN CHASE & CO added 6,981,234 shares (+inf%) to their portfolio in Q2 2026, for an estimated $236,524,207
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 6,593,221 shares (+inf%) to their portfolio in Q2 2026, for an estimated $223,378,327
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,775,221 shares (+6595.0%) to their portfolio in Q2 2026, for an estimated $127,904,487
CAPITAL WORLD INVESTORS added 3,702,469 shares (+41.9%) to their portfolio in Q2 2026, for an estimated $125,439,649
KRANOT HISHTALMUT LE MORIM VE GANANOT HAVERA MENAHELET LTD added 2,912,281 shares (+inf%) to their portfolio in Q2 2026, for an estimated $98,668,080

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TEVA Analyst Ratings

Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.

$TEVA Price Targets

Multiple analysts have issued price targets for $TEVA recently. We have seen 5 analysts offer price targets for $TEVA in the last 6 months, with a median target of $42.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $40.0 on 05/06/2026
Les Sulewski from Truist Securities set a target price of $45.0 on 04/30/2026
David Amsellem from Piper Sandler set a target price of $42.0 on 04/30/2026
Ashwani Verma from UBS set a target price of $42.0 on 04/30/2026
Chris Schott from JP Morgan set a target price of $40.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.